European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Glaxosmithkline Intellectual Property (NO.3) Ltd., Stevenage

Watch
Glaxosmithkline Intellectual Property (NO.3) Ltd.

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Premium Service
Unlock Dossier
What is a Dossier?
A dossier provides comprehensive company details as a PDF, together with all underlying original publications and original data in one place.
The download feature is exclusively available for our paid plan. Upgrade your account to access:
Quick Dossier
Entire company details as a PDF
Power Dossier
Entire company details along with all original publications / original data bundled in a ZIP file
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more
Learn more
View plans

Name

Glaxosmithkline Intellectual Property (NO.3) Ltd.

Identification

Chp
Companies House 11480952
Lei
5493009HTKVB0TC78D91

Address

Gunnels Wood Road, Gsk Medicines Research Centre, Stevenage SG1 2NY, United Kingdom
980 Great West Road Brentford Middlesex, United Kingdom
Gsk Medicines Research Centre Gunnels Wood Road Stevenage, United Kingdom

Corporate purpose

74.90/9
Other professional, scientific and technical activities (not including environmental consultancy or quantity surveying) n.e.c.

Financial performance

Earnings

For this company, Earnings numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Revenue

For this company, Revenue numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Total assets

For this company, Total assets numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

History

Persons

Marketing & Tech

Network

Loading network

Legal Structure

Current legal representatives Legal form information Premium
Premium
5Director
2Director
1Secretary
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans
tax haven banner
Ownership relations Premium + Ownership & Flags add-on
Premium + Ownership & Flags add-on
Shareholders and Investors
2 known active shareholders
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Financials

Key Performance Indicators Financial · Mktg & Tech Premium
Premium
Base/share capital
Total assets
Earnings
Revenue
Revenue CAGR
Return on sales
Equity
Equity ratio
Taxes
Receivables
Liabilities
Patents
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Publications

17 Sept 2026 also 29/09/2025, 28/10/2024, 25/10/2023, 14/10/2022, 04/08/2022, 26/07/2021, 29/07/2020
Confirmation statement made with no updates
20 Aug 2026
Annual report for the year ending 31/12/2025
20 Aug 2026 also 19/08/2025, 17/08/2024, 16/08/2023, 19/08/2022, 20/05/2021
Consolidated accounts of parent company for subsidiary company period ending 31/12/25
20 Aug 2026 also 17/08/2024, 20/05/2021
Audit exemption statement of guarantee by parent company for period ending 31/12/25 …
17 Jun 2026
Patent: Preparation of a P2X3 antagonist
1 Apr 2026
Patent: Rnai for the treatment of hepatitis B virus infection
19 Aug 2025
Annual report for the year ending 31/12/2024
19 Aug 2025
Notice of agreement to exemption from audit of accounts for period ending 31/12/24 …
15 Jul 2025
Director: Anna M. H. Fent
9 Jul 2025
No longer Director: Jemma-L. Reynolds
7 May 2025
Patent: Kristalline Formen des P2X3-Modulators Methyl (S)-2-((2-(2,6-Difluoro-4-(Methylcarbamoyl )Phenyl)-7-Methylimidazo[1,2-A]Pyridin-3-YL)Methyl)Morpholin-4-Carboxylat
Year 2024 in Epobase
5 European patent filings: Process of Manufacture of P2X3 Antagonists Including Camlipixant …
27 Sept 2024
Director: C. Barcelo Igles
20 Sept 2024
Director's details changed for Mrs Demet Gurunlu Russ
17 Sept 2024
Director's details changed for Mr Graham Paul Rivers · Director's details changed for Mrs Jemma-Louise Reynolds …
11 Sept 2024
Director's details changed for The Wellcome Foundation Limited
30 Aug 2024
Annual report for the year ending 31/12/2023
31 Jul 2024
No longer Director: Gregory M. Reinaud
18 Jul 2024
Address
12 Jul 2024
Appointment of Mrs Demet Gurunlu Russ as a director
5 Jul 2024
No longer Director: Jill Dawn Anderson
15 Apr 2024
Director: Jemma-L. Reynolds
2 Feb 2024
Director: Gregory M. Reinaud
Year 2023 in Epobase
4 European patent filings: Antigen Binding Proteins …
20 Sept 2023
No longer Director: Ziba Shamsi
16 Aug 2023
Annual report for the year ending 31/12/2022
16 Aug 2023
Companies House - Filing
2 Aug 2023
Director: Graham Paul Rivers
20 Jul 2023
No longer Director: James R. Wheatcroft
9 Jun 2023
Address
6 Jun 2023
Address
3 Mar 2023
Director: Jill Dawn Anderson
2 Mar 2023
No longer Director: Jerome Andries
3 Nov 2022
Director: Ziba Shamsi
2 Nov 2022
Termination of appointment of Kate Sophie Priestman as a director
6 Sept 2022
Annual report for the year ending 31/12/2021
6 Sept 2022
Audit exemption statement of guarantee by parent company for period ending 31/12/21
19 Aug 2022
Notice of agreement to exemption from audit of accounts for period ending 31/12/21
16 Aug 2022
Patent: Preparation of a P2X3 antagonist
7 Jul 2022
Patent: USE of Oligonucleotides for Individuals with Renal Impairment
12 Jan 2022
Patent: Inhibitors of TRPM3 and Their Uses
27 Sept 2021
Annual report for the year ending 31/12/2020
12 Feb 2021
Patent: P2X3 modulators
4 Aug 2020
Annual report for the year ending 31/12/2019
Year 2020 in Epobase
4 European patent filings: Covalent Multi-Specific Antibody …
3 Sept 2019
Director: James R. Wheatcroft
23 Jul 2019
Confirmation statement made with updates
7 May 2019
No longer Director: Simon Paul Dingemans
23 Jan 2019
No longer Secretary (1) · Secretary: Edinburgh Pharmaceutical Industries Ltd
20 Sept 2018
Resolution of adoption of Articles of Association (ADOPT ARTICLES)
14 Sept 2018
Patent: Selective P2X3 Antagonists for USE in Treating Chronic Cough without Loss of Taste Response
13 Sept 2018
Current accounting period extended from 2019-07-31 to 2019-12-31
24 Jul 2018
Reg­is­tra­tion: 24/07/2018 · Director (4) · Secretary (1) · Director: Edinburgh Pharmaceutical Industries Ltd., The Wellcome Foundation Ltd. · Capital: £100.00
There are no publications matching your search.

Mentions

26 Oct 2026 in Ler
Direct parent
26 Oct 2026 in Ler
Ultimate parent
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Printing is only available to North Data premium service subscribers.